- IHH Healthcare's 1Q25 results were in-line with our/consensus expectations on the back of stable revenue growth and EBITDA margins across all key segments.
- Despite some geopolitical, structural and regulatory challenges across the different countries, we stay bullish on resilient demand and growing case-mix intensity as IHH Healthcare remains focused on organic and opportunistic inorganic growth.
- - Read this at SGinvestors.io -
Results in-line with expectations
- IHH Healthcare's 1Q25/3M25 core net profit (ex-MFRS 129) of MYR521m (-11% y-o-y, +10% q-o-q) was in-line at 24%/26% of our/consensus FY estimates.
- - Read this at SGinvestors.io -
- Weakest growth came from Singapore (due to ongoing reno-works at Mt Elizabeth Hospital).
Accommodating for higher costs
- Read more at SGinvestors.io.
